Seagen, a wholly owned subsidiary of Pfizer
Clinical trials sponsored by Seagen, a wholly owned subsidiary of Pfizer, explained in plain language.
Biotech company developing antibody-drug conjugates for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise for tough bladder cancer Results expected Dec 2026 (estimated)
- New drug combo aims to outdo chemo for advanced bladder cancer Results expected Jan 2027 (estimated)
- New cancer drug sigvotatug vedotin enters human trials Results expected Jun 2027 (estimated)
- New drug combo targets tough blood cancers in early trial Results expected Jul 2027 (estimated)
-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Drug combo shows promise for Tough-to-Treat cancers
Disease control CompletedThis study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis study tested a combination of two drugs, tucatinib and trastuzumab deruxtecan (T-DXd), in 70 people with advanced HER2-positive breast cancer that had spread or couldn't be removed by surgery. The goal was to see how well the drugs shrank tumors and what side effects occurre…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug shows promise in battle against advanced cervical cancer
Disease control CompletedThis study tested whether a new drug called tisotumab vedotin works better than standard chemotherapy for people with cervical cancer that has spread or returned. Over 500 participants were randomly assigned to receive either the new drug or one of five chemotherapy options. The …
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cancer drug SGN-B6A tested for safety in chinese patients
Disease control CompletedThis early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC